Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AsiDNA,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results
Details : The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients with advanced solid tumors.
Brand Name : AsiDNA
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 09, 2020
Lead Product(s) : AsiDNA,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : This patent will provide a term of protection until 2036. It completes the already robust set of patent families protecting AsiDNA™ and its related compounds, alone or in combination.
Brand Name : AsiDNA
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 22, 2020
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan
Details : Revocan phase 1b/2 study is designed to evaluate the effect of AsiDNA™, Onxeo’s first-in-class DDR inhibitor, on the acquired resistance to PARP inhibitor (PARPi) niraparib for second line maintenance treatment of relapsed ovarian cancer.
Brand Name : AsiDNA
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 21, 2020
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AsiDNA,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose used today in the ongoing DRIIV-1b and REVOCAN studies of AsiDNA™ in combination with chemotherapy and PARP inhibitors .
Brand Name : AsiDNA
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 27, 2020
Lead Product(s) : AsiDNA,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Onxeo Announces Approval of the REVocan Study by Regulatory Authorities
Details : The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 29, 2020
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preclinical data supports the differentiated ability of AsiDNA™, its first-in-class DNA Damage Response (DDR) inhibitor, to reverse resistance to PARP inhibitors (PARPi) by preventing death-tolerant cells (DTC) regrowth.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 19, 2020
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement
Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $6.6 million
April 06, 2020
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement
Lead Product(s) : OX401
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020
Details : The data will showcase the high affinity with PARP that leads to DDR inhibition, metabolic exhaustion and activation of the innate immune response, specifically in tumoral cells.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
February 27, 2020
Lead Product(s) : OX401
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The REVOCAN ph 1b/2 study, will evaluate the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in 2nd line maintenance treatment of relapsed ovarian cancer.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
January 29, 2020
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Gustave Roussy
Deal Size : Undisclosed
Deal Type : Agreement
Details : The collaboration aims to conduct the REVOCAN phase 1b/2 study designed to evaluate the effect of AsiDNA, Onxeo’s first-in-class DDR inhibitor, on the acquired resistance to PARPi niraparib in its approved indication for the treatment of relapsed ovari...
Brand Name : AsiDNA
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 29, 2020
Lead Product(s) : AsiDNA,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Gustave Roussy
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?